Lynk Pharmaceuticals Co., Ltd

Quick facts

Phase 3 pipeline

• LNK01001 · Oncology
  LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.

Phase 2 pipeline

• LNK01001 Dose A
• LNK01001 Dose B
• LNK01004 ointment 0.3%
• LNK01004 ointment 1.0%

Phase 1 pipeline

• LNK01004 ointment 1.5%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lynk Pharmaceuticals Co., Ltd portfolio CI brief
• Lynk Pharmaceuticals Co., Ltd pipeline updates RSS